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Abstract Strong evidence suggests that type 2 diabetes con-
fers a stronger excess risk of cardiovascular diseases in wom-
en than inmen; with women having a 27% higher relative risk
of stroke and a 44 % higher relative risk of coronary heart
disease compared with men. The mechanisms that underpin
these sex differences in the associations between diabetes and
cardiovascular disease risk are not fully understood. Some of
the excess risk may be the result of a sex disparity in the
management and treatment of diabetes, to the detriment of
women. However, accruing evidence suggests that real bio-
logical differences between men and women underpin the
excess risk of diabetes-related cardiovascular risk in women
such that there is a greater decline in risk factor status in
women than in men in the transition from normoglycemia to
overt diabetes. This greater risk factor decline appears to
be associated with women having to put on more weight than
men, and thus attain a higher body mass index, to develop
diabetes. Further studies addressing the mechanisms respon-
sible for sex differences in the excess risk of cardiovascular
diseases associated with diabetes are needed to improve the
prevention and management of diabetes in clinical practise.
Keywords Diabetes .Cardiovasculardisease .Coronaryheart
disease . Stroke . Sex differences . Men .Women
Introduction
Diabetes mellitus is a major health concern; 382 million indi-
viduals or 8.3 % of the adult population worldwide have dia-
betes, and an additional 175 million people are unaware that
they may have diabetes. Most people with diabetes live in
low- and middle-income countries; countries in Oceania,
North Africa and the Middle East have the highest prevalence
of diabetes, with rates in these countries ranging from 21–
25 % in men and 21–32 % in women (Fig. 1) [1, 2]. The
prevalence of diabetes is expected to rise by 55 % to 592
million individuals by 2035 [1]; whilst much of this increase
is driven by population growth and ageing, other key contrib-
utors are the rapid growth in the prevalence of overweight and
obesity and the increasing lack of physical activity. Trends in
the prevalence of diabetes vary substantially between regions
and sexes, which is inherent to substantial biological, socio-
economic and societal differences (Fig. 2) [2, 3]. Type 2 dia-
betes is the most common type of diabetes and accounts for 85
to 95 % of all diabetes, with the remainder comprising mainly
of type 1 diabetes—one of the most common autoimmune
diseases.
Diabetes and its complications are major causes of early
death in most countries. Approximately 5.1 million individ-
uals died from diabetes in 2013, accounting for 8.4 % of
global all-cause mortality amongst adults [1]. Although the
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global number of deaths due to diabetes is similar between
men and women, there are important differences in the global
distribution of these deaths [1]. About 25 % more men than
women die of diabetes in the Western Pacific region, whereas
diabetes accounts for 30%more deaths in women than in men
in Southeast Asia, and for over 50%more deaths in women in
Fig. 1 Prevalence (%) of diabetes in adults (20–79 years) in 2013. Figure is obtained from reference [1]
Fig. 2 Percentage growth in age-
standardised diabetes prevalence,
1980–2008, by region.
Reproduced, with the permission
of the publisher, from reference [3]
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Africa. This disparity may in part be due to higher rates of
mortality from other causes, biological factors, or because of
poorer access to healthcare amongst women in some regions.
Diabetes also poses a large economic and social burden on
individuals and families, national health systems and coun-
tries. Health spending on diabetes accounted for 11 % of total
health expenditure worldwide in 2013, equating to 548 billion
USD and, unsurprisingly, only 20 % of this global health
expenditure occurred in low- and middle-income countries,
where about 80 % of all individuals with diabetes live [1].
Hence, whilst the impact of the diabetes epidemic is global,
it disproportionally affects those living in socially and eco-
nomically disadvantaged conditions.
Sex Differences in the Excess Risk of Cardiovascular
Diseases Associated with Type 2 Diabetes
Considerable sex differences exist in the occurrence of the
various manifestations of cardiovascular disease (CVD).
Men have a higher risk of coronary heart disease (CHD),
whereas women, who tend to have a longer life expectancy,
have a similar or greater propensity of developing stroke [4,
5]. Cardiovascular disease is the most common underlying
cause of death, accounting for 52 % of deaths in type 2 dia-
betes [6]. This estimate, however, is based on the assumption
that the associations between diabetes and CVD outcomes are
equivalent between women and men. An accruing body of
literature shows that there are appreciable and clinically rele-
vant differences in how diabetes affects the risk of CVD in
men and women (Fig. 3). A recent pooled analysis
summarising data from 64 cohorts, including nearly 900,000
individuals and over 28,000 incident CHD events, showed
that the presence of diabetes nearly tripled the risk of incident
CHD in women (RR 2.82 [95 % CI 2.35; 3.38]), whereas it
little more than doubled the risk in men (RR 2.16 [95 % CI
1.82; 2.56]) [7•]. Therefore, diabetes conferred a 44 % (95 %
CI 27–63 %) greater excess risk for incident CHD in women
compared with men. This estimate is comparable to the 46 %
excess risk for fatal CHD in women with diabetes found in a
previous analysis [8]. In addition, a pooled analysis on data
from 750,000 individuals and more than 12,000 incident
stroke events provided strong evidence that women with dia-
betes mellitus have a 27 % (95 % CI 10, 46 %) greater in-
creased risk of stroke compared with their male counterparts;
the pooled relative risk of stroke associated with diabetes was
2.28 (95 % CI 1.93, 2.69) in women and 1.83 (95 % CI 1.60,
2.08) in men, independent of sex differences in other major
cardiovascular risk factors [9•]. This sex differential was seen
consistently across major predefined stroke, study and partic-
ipant subtypes, which included a comparison of individuals
from Asian and non-Asian populations. Furthermore, recent
analyses of routinely collected health care data from the UK
suggests that diabetes has a stronger association with the risk
of CVD inwomen than inmen; however, only amongst young
people [10]. This may be explained by findings from previous
large-scale studies that show that the effects of diabetes on the
risk of CVD generally attenuate with age. Sex differences may
continue to exist after the diagnosis of diabetes; a recent study
suggested that the risk of stroke associated with higher HbA1c
was greater in women than in men with type 2 diabetes; each
1 % increase in baseline HbA1c was associated with a 5 %
(95 % CI 1.02, 1.07) higher relative risk of stroke in women
and a 1 % (95 % CI 0.99, 1.04) higher relative risk of stroke in
men [11].
Sex Differences in the Management of Diabetes
A sex disparity in the management and treatment of cardio-
vascular risk factors in individuals with diabetes, to the detri-
ment of women, possibly explains the excess risk of CVD in
Fig. 3 Relative risk (RR) and
women:men ratio of relative risks
(RRR) for coronary heart disease
(CHD) and stroke in women and
men with diabetes versus without
diabetes. Vertical bars represent
95 % confidence intervals. Data
were obtained from references
[7•, 9•]
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women with diabetes compared to men. Historically, women
with diabetes were more likely to have a more adverse cardio-
vascular risk profile, were treated less aggressively and were
less likely to achieve recommended levels of risk factors com-
pared to male counterparts [12–16].Whilst access to treatment
has become more equitable between the sexes over the past
decade, especially in high income countries, sex differences in
medication use and risk factor control continue to exist [17,
18]. For example, the 2012–2013 report of the National Dia-
betes Audit on nearly 2 million individuals with diabetes in
the UK showed that 58 % of women and 62 % of men with
diabetes received recommended care processes, and that 34 %
of women and 37 % of men achieved treatment targets for
HbA1c, blood pressure and cholesterol [17]. After controlling
for key confounding factors, such as age, ethnicity, depriva-
tion group, body mass index (BMI) and duration of diabetes,
women were 15 % less likely than men to meet all recom-
mended care processes. Furthermore, other recent studies
have shown that, even when treated similarly, women with
diabetes are less likely than men to achieve target values for
cardiovascular risk factors [19, 20]. We therefore hypothesise
that sex differences in the management of diabetes alone are
unlikely to explain all of the excess relative risk of CHD and
stroke in women with diabetes. This is also supported by the
results from the meta-analyses [7•, 8, 9•], which showed that
the impact of accounting for levels of cardiovascular risk fac-
tors on the estimated excess risk of CHD and stroke associated
with diabetes was similar in men and women.
Sex Differences in Cardiovascular Risk Factors
in the Development of Diabetes
Women without diabetes generally have more favourable
levels of cardiovascular risk factors than men, but this pattern
may reverse with a decline in glucose tolerance [8, 9•]. Several
studies have shown that the deterioration in cardiovascular
risk factor levels between individuals with and without type
2 diabetes is greater in women than in men (Table 1) [21–26].
The British Regional Heart Study and BritishWomen’s Health
and Heart Study found that women with diabetes had greater
relative differences in many established and novel cardiovas-
cular risk factors than men with diabetes including markers of
coagulation, fibrinolysis, lipids and blood pressure, which
were potentially mediated by greater differences in central
adiposity and insulin resistance in women [23]. Hence, since
many cardiovascular risk factors change to a greater extent in
women than in men, women may have more cardiometabolic
reserves and have to undergo greater metabolic deterioration
to develop diabetes than do men. This hypothesis is supported
by studies that found that levels of cardiovascular risk factors
are already different between men and women before the con-
version to a state of impaired glucose tolerance [27, 28].
Women, but not men, who progress from normoglycemia to
pre-diabetes have higher levels of endothelial dysfunction,
higher blood pressure and more abnormalities in their fibrino-
lysis and thrombosis pathways, compared to those who do not
[28]. Therefore, the diabetes-related excess risk of CVD in
women may not necessarily be due to any significant sex
difference in the effects and complications of diabetes itself,
but rather the result of a greater deterioration in cardiovascular
risk factor levels in women compared to men in the transition
to diabetes. Consequently, women diagnosed with diabetes
may already be at a worse starting point than comparable
men before treatment begins.
Sex Differences in Body Mass Index at the Time
of Diagnosis
Overweight and obesity is the key risk factor for the develop-
ment of diabetes. Even though the magnitude of the associa-
tion between BMI and diabetes is similar in men and women,
studies have demonstrated that men need to attain a lower
Table 1 Age-adjusted and multiple-adjusted mean differencea (95 % confidence interval) in baseline risk factor levels amongst men and women with
and without diabetes
Risk factor Age-adjusted mean difference Multiple-adjusted mean difference
Men Women Men Women
Systolic blood pressure (mmHg) 5.33 (5.09; 5.58) 6.79 (6.40; 7.18) 4.18 (3.93; 4.44) 4.70 (4.26; 5.14)
Total cholesterol (mmol/L) 0.22 (0.20; 0.23) 0.24 (0.22; 0.27) 0.15 (0.13; 0.17) 0.14 (0.11; 0.17)
HDL cholesterol (mmol/L) −0.09 (−0.11; −0.08) −0.16 (−0.17; −0.14) −0.06 (−0.08; −0.05) −0.11 (−0.13; −0.09)
Body Mass Index (kg/m2) 1.01 (0.97; 1.06) 2.00 (1.91; 2.09) 0.64 (0.59; 0.68) 1.66 (1.57; 1.75)
Waist circumference (cm) 5.27 (4.79; 5.75) 9.06 (8.53; 9.59) 0.45 (0.21; 0.70) 2.20 (1.90; 2.50)
HDL high density lipoprotein cholesterol
a The difference is diabetes minus non-diabetes. Pooled data from the Asia Pacific Cohort Studies Collaboration, Atherosclerosis Risk in Communities
Study, National Health and Nutrition Examination Survey III and Scottish Heart Health Extended Cohort. Multiple-adjusted mean differences are, where
appropriate, adjusted for age, systolic blood pressure, smoking, bodymass index and total cholesterol. Reproduced, with the permission of the publisher,
from reference [9•]
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average BMI to be diagnosed with diabetes compared to
women [29, 30]. For example, in a population-based diabetes
register in Scotland, mean BMI closest to date of diagnosis of
type 2 diabetes mellitus was 31.8 kg/m2 in men and 33.7 kg/
m2 in women (Fig. 4) [30]. Results from the UK General
Practice Research Database were almost identical to these
Scottish findings; the age-adjusted average BMI at diagnosis
of diabetes was nearly 2 kg/m2 higher in women than in men
[29]. Both studies demonstrated that the difference in BMI at
the time of diagnosis of diabetes was most marked at younger
ages and narrowed with advancing age. Moreover, the Scot-
tish data showed that HbA1c levels within 1 year of diagnoses
were broadly similar in men and women, indicating that they
were diagnosed at a similar stage of disease [30]. This implies
that, at the same level of BMI, adult men without diabetes are
more resistant to insulin than women or, similarly, that adult
women are at lower risk of diabetes at an equivalent BMI.
The sex disparity in BMI at the time of diagnosis of diabe-
tes can be linked to differential patterns of adiposity storage in
men and women, and also to a healthier CVD risk profile in
women without diabetes versus their male counterparts, as
discussed above [31, 32•, 33]. Women, in general, have great-
er subcutaneous fat storage capacities and, linked to this, carry
less visceral (i.e. more hazardous) fat than men. Since subcu-
taneous storage capacity is lower in men, excess adipose tissue
is placed more rapidly into visceral and ectopic tissues, such
as the liver and the skeletal muscle, which in turns leads to
insulin resistance and interferes with insulin signalling path-
ways [34]. Women need to accumulate a greater amount of
total adiposity, i.e. require attaining a higher level of BMI,
than men for their subcutaneous storage to become exhausted,
and to reach the same harmful visceral and ectopic fat depo-
sition required to become insulin resistant and to develop di-
abetes [32•, 34].Moreover, women, on average, tend to have a
greater deterioration in metabolic risk factors including levels
of blood pressure, lipids and inflammatory markers, and are
likely to have accumulated more time living in a hazardous
metabolic environment exacerbated by being in a pre-diabetic
state compared with men in whom the deterioration in meta-
bolic indices is less marked. This sex difference in the prefer-
ential location of fat storage (subcutaneous in women versus
visceral/ectopic in men) and its associated metabolic changes
may be crucial to the differential rates of development of dia-
betes (lower diabetes incidence in adult women) and, once
diabetes ensues, to differential complication rates as discussed
herein.
Clinical Implications
Diabetes develops over decades; a recent study demonstrated
that men, on average, have pre-diabetes for 8 years, and wom-
en for 10 years before they progress to overt diabetes [35].
This window presents an opportunity for identifying individ-
uals at high risk for diabetes, and subsequently, for timely
Fig. 4 Mean body mass index by
age at diagnosis of type 2 diabetes
for men (black) and women
(white) aged between 30 and
90 years at diagnosis and with
BMI >25 kg/m2 from the Scottish
Care Information Diabetes
Collaboration (SCI-DC) dataset.
Patients who died within 2 years
of BMI determination were
excluded. Vertical bars represent
95 % CIs around the mean.
Reproduced, with the permission
of the publisher, from reference
[30]
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intervention to prevent or delay the onset of diabetes. The
widening acceptance of diabetes diagnosis and its high risk
states, via either fasting glucose (5.5 to 6.9 mmol/L as high
risk) or HbA1c (6.0 to 6.4 % as high risk), has facilitated
screening for, and diagnosis of, diabetes in clinical practise
[36, 37]. HbA1c has the advantage of not requiring individ-
uals to fast, enabling diagnosis to be done at any time and in
any clinical situation, thus improving early detection of high
risk for, or existing, diabetes. What is needed now is better
facilitation of lifestyle changes to help men and women at risk
to favourably change their weight, or weight trajectory, to
delay or prevent the onset of diabetes. There is evidence that
commercial weight loss companies do better than routine clin-
ical services in helping people to lose weight and that women,
in particular, are more comfortable with such services [38].
Similarly, increased awareness of the magnitude and timing of
the risk of diabetes after gestational diabetes could provide an
opportunity to facilitate lifestyle interventions that might pre-
vent or delay the onset of type 2 diabetes in affected women
[39, 40]. Regular monitoring of HbA1c in women with gesta-
tional diabetes will help facilitate risk screening. As cardio-
vascular risk factors escalate more in women as they transition
to diabetes, physicians should take particular care to conduct a
comprehensive cardiovascular risk assessment in women
(whilst not neglecting men) noted to be at elevated risk of
diabetes. These ideas fit with the need, wherever possible, to
combine risk assessments for CVD and diabetes in primary
care, in simple and pragmatic ways, as recently argued [41].
Finally, all physicians should bemade aware that development
of diabetes is associated with a greater increase in cardiovas-
cular risk in women than in men so that they should, at the
very least, treat women with diabetes as aggressively as they
do with their male counterparts.
Conclusion
There is accumulating evidence that the impact of type 2 dia-
betes on cardiovascular risk differs profoundly between the
sexes and is more hazardous for women than for men. Al-
though this may in part reflect a treatment disparity between
women and men with diabetes, there are several lines of evi-
dence to suggest that real behavioural and biological sex dif-
ferences exist which may underpin the excess risk of diabetes-
related cardiovascular risk in women. A greater deterioration
in risk factor status in women than in men as they transition
to diabetes, before the development of overt diabetes,
appears to play a crucial role. This greater risk factor decline
may in turn be related to women having to put on more weight
than men (and thus attain a higher BMI) to develop diabetes.
Future work aimed further clarification and understanding of
the mechanisms responsible for sex differences in the excess
risk of cardiovascular diseases associated with diabetes will be
needed to improve the prevention and management of diabe-
tes in clinical practise.
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